A New Era in Alzheimer’s Research
Early detection remains one of the greatest challenges—and greatest hopes—in the fight against Alzheimer’s disease. While imaging and cerebrospinal fluid (CSF) biomarkers have long been the gold standard, they’re often costly, invasive, and inaccessible in routine clinical settings. That’s why blood-based biomarkers—especially phosphorylated tau (pTau) isoforms like pTau(181)—have become a focal point for transforming Alzheimer’s diagnosis and monitoring.
The challenge? Detecting pTau(181) at ultra-low blood concentrations has historically required specialized equipment or expensive digital platforms. With Exazym®, that’s no longer the case.
Breakthrough Sensitivity, Standard Workflows
Cavidi’s proprietary BOLD™ amplification platform enables researchers to reach ultrasensitive detection levels—including sub-picogram-per-milliliter concentrations of pTau(181)—using standard immunoassay workflows.
In our latest white paper, we demonstrate how Exazym® delivered a 60X signal boost in a human pTau(181) sandwich ELISA. The results show how labs can achieve the sensitivity required for blood-based Alzheimer’s research without investing in new equipment or switching assay formats.
Why pTau(181) Matters
Among various phosphorylated tau species, pTau(181) has emerged as a leading blood-based biomarker for Alzheimer’s pathology. It reflects tau hyperphosphorylation and correlates with neurofibrillary tangle burden—making it a reliable indicator of disease progression, even in pre-symptomatic individuals.
The ability to measure pTau(181) at extremely low levels in plasma or serum opens doors to:
- Earlier diagnosis before clinical symptoms appear
- Better patient stratification for clinical trials
- More accessible screening across diverse care settings
- Precise monitoring of therapeutic interventions
Democratizing Neurobiomarker Research
Every 65 seconds, someone develops Alzheimer’s disease. By 2050, nearly 13 million Americans could be affected. Yet the analytical tools needed to study this disease have remained largely confined to specialized laboratories with expensive digital platforms.
At Cavidi, our goal is to make ultra-sensitive detection accessible—especially in neurology, where critical signals often hide at the edge of detectability.
Our Neuroscience White Paper outlines how Exazym is helping researchers tackle low-abundance analytes across Alzheimer’s, Parkinson’s, and other neurodegenerative conditions, with real data from academic and industry partners.
For World Alzheimer’s Day—and Beyond
This September 21, as the world focuses on Alzheimer’s awareness, we invite you to explore how better analytical tools can accelerate progress.
If your lab is working to detect pTau(181) or other neurodegenerative biomarkers, Exazym delivers the sensitivity you need—without the overhead that’s held back blood-based testing.
The path to better Alzheimer’s outcomes runs through better detection. And better detection is now within reach.
Download our Neuroscience White Paper